Plaque Psoriasis

Study shows ustekinumab more effective at certain doses and in treatment-naïve patients. Several factors associated with diminished treatment response also identified.

A trio of phase 3 trials will evaluate the safety and efficacy of certolizumab pegol evaluated for the treatment of adults with moderate-to-severe chronic plaque psoriasis.

A round up of recent research results on plaque psoriasis treatment with itolizumab, apitherapy, and ponesimod.

Cosentyx (secukinumab) has been approved in Japan for the treatment of psoriasis vulgaris (also known as plaque psoriasis) and psoriatic arthritis.

Researchers report that patients diagnosed with moderate to severe plaque psoriasis who were treated with ixekizumab, an investigational anti-interleukin-17A monoclonal antibody, have maintained a favorable clinical response over a year-long course of treatment.

Researchers compared the effectiveness of biologics approved in Europe for the treatment of plaque psoriasis based on their performance as measured by primary endpoints in clinical trials.

Amgen and AstraZeneca recently announced AMAGINE-2TM, a pivotal, multi-arm Phase 3 clinical trial, met all primary endpoints for brodalumab, an experimental drug designed for moderate to severe plaque psoriasis treatment.

The compound AIN457 (secukinumab) has been granted a unanimous vote of support for approval from the Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration.

Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.

A new drug with the potential to join the existing class of monoclonal antibodies (mAbs) for plaque psoriasis has shown promising results in a Phase II study.

Ponesimod, a selective S1P1 receptor agonist, has been shown to be efficacious for improving both disease and quality of life markers in patients with moderate to severe chronic plaque psoriasis.

Otezla (apremilast) is an oral, selective phosphodiesterase 4 (PDE4) inhibitor for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.

Ixekizumab, a drug being evaluated for the treatment of moderate-to-severe chronic plaque psoriasis, continues to demonstrate efficacy and safety in Phase III trials.

The National Psoriasis Foundation (NPF) recently announced a number of new programs and a five-year strategic mission for the organization with initiatives that are designed to increase research and uncover new treatments for all forms of psoriasis and psoriatic disease.

The National Psoriasis Foundation (NPF) announced in a press release that the Centers for Medicare and Medicaid Services will not cut reimbursement for phototherapy in 2015.

The US Food and Drug Administration recently announced its approval of a new medication for the treatment of rheumatoid arthritis.

As research continues to be done to find the most efficient treatment for patients with plaque psoriasis a study was recently published looking at how the inclusion of topical corticosteroids can benefit the care provided.

For more than 70 years methotrexate has been a popular tool in the prescription toolkit of doctors around the world. However, a recent case report by a team from the United Kingdom showed how important it is for prescribing doctors to also keep a close eye on some of the well-known adverse events associated with the medication.

Patients with psoriasis, psoriatic arthritis, or both conditions felt their quality of life decreased if they experienced condition symptoms in more parts of their body.

Cardiovascular risk related to severity of inflammation, but not associated with disease duration

Although tofacitinib is typically used to treat rheumatoid arthritis, researchers at Yale University discovered the drug effectively reversed alopecia universalis in a patient with plaque psoriasis.

Patients with psoriasis could see relief from their condition following the results of a study that examined the impact of the stimulation of the aryl hydrocarbon receptor.

Study results announced at the 11th European Academy of Dermatology and Venereology Spring Symposium show tofacitinib met its two primary efficacy endpoints.

Study of novel investigational IL-17 receptor antibody meets all primary and secondary endpoints.

Tim Gunn, Pfizer, and Amgen teamed up to offer style and fashion advice for patients who have been diagnosed with psoriasis.